[SCHEDULE 13G] Reviva Pharmaceuticals Holdings, Inc. SEC Filing
Highbridge Capital Management, LLC reports beneficial ownership of warrants convertible into 8,000,000 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing 9.9% of the class after giving effect to an offering described in the issuer's June 26, 2025 prospectus supplement and subject to a contractual 9.9% blocker. The filing clarifies the 8,000,000 figure reflects full exercise of the reported warrants but notes Highbridge cannot exercise warrants to the extent doing so would exceed the 9.9% ownership limit, so the actual exercisable shares are limited by that blocker. The reporting person is an investment adviser filing on behalf of Highbridge funds and discloses that one fund, Highbridge Tactical Credit Master Fund, L.P., holds more than 5% of the class.
Highbridge Capital Management, LLC dichiara la propriet脿 effettiva di warrant convertibili in 8.000.000 azioni ordinarie di Reviva Pharmaceuticals Holdings, Inc., pari al 9,9% della categoria dopo aver considerato un鈥檕fferta descritta nel supplemento al prospetto dell鈥檈mittente del 26 giugno 2025 e soggette a una clausola contrattuale di blocco del 9,9%. Il deposito chiarisce che la cifra di 8.000.000 riflette l鈥檈sercizio completo dei warrant dichiarati, ma precisa che Highbridge non pu貌 esercitare i warrant nella misura in cui ci貌 porterebbe a superare il limite di propriet脿 del 9,9%, quindi il numero effettivamente esercitabile 猫 limitato da tale clausola. La persona che presenta la dichiarazione 猫 un gestore di investimenti che agisce per conto dei fondi Highbridge e dichiara che un fondo, Highbridge Tactical Credit Master Fund, L.P., detiene oltre il 5% della categoria.
Highbridge Capital Management, LLC informa de la propiedad beneficiaria de warrants convertibles en 8.000.000 acciones ordinarias de Reviva Pharmaceuticals Holdings, Inc., lo que representa el 9,9% de la clase despu茅s de considerar una oferta descrita en el suplemento del prospecto del emisor del 26 de junio de 2025 y sujeto a un contratual bloqueo del 9,9%. La presentaci贸n aclara que la cifra de 8.000.000 refleja el ejercicio total de los warrants informados, pero se帽ala que Highbridge no puede ejercer warrants en la medida en que ello supere el l铆mite de propiedad del 9,9%, por lo que las acciones realmente ejercitables est谩n limitadas por dicho bloqueo. La persona que informa es un asesor de inversiones que presenta en nombre de los fondos Highbridge y divulga que un fondo, Highbridge Tactical Credit Master Fund, L.P., posee m谩s del 5% de la clase.
Highbridge Capital Management, LLC電� Reviva Pharmaceuticals Holdings, Inc. 氤错喌欤� 8,000,000欤茧 鞝勴櫂 臧�電ロ暅 鞗岆煱韸胳潣 鞁れ鞝� 靻岇湢毳� 氤搓碃頃橂┌, 鞚措姅 氚滍枆鞚胳澊 2025雲� 6鞗� 26鞚检瀽 氤挫订靹る獏靹滌棎 旮办灛霅� 瓿惦毳� 氚橃榿頃� 頉� 頃措嫻 膦呺鞚� 9.9%鞐� 頃措嫻頃橁碃 瓿勳暯靸� 9.9% 彀嫧臁绊暛鞚� 鞝侅毄鞚� 氚涭姷雼堧嫟. 鞝滌稖靹滊電� 8,000,000鞚措澕電� 靾橃箻臧� 氤搓碃霅� 鞗岆煱韸胳潣 鞝勳暋 頄夓偓 旮办鞛勳潉 氇呿檿頌� 頃橂倶, Highbridge電� 靻岇湢 牍勳湪鞚� 9.9%毳� 齑堦臣頃橁矊 霅橂姅 氩旍渼鞐愳劀電� 鞗岆煱韸鸽ゼ 頄夓偓頃� 靾� 鞐嗢溂氙�搿� 鞁れ牅搿� 頄夓偓 臧�電ロ暅 欤检嫕 靾橂姅 攴� 彀嫧臁绊暛鞐� 鞚橅暣 鞝滍暅霅滊嫟瓿� 氇呾嫓頃╇媹雼�. 氤搓碃鞚胳潃 Highbridge 韼�霌滊ゼ 雽�鞁犿晿鞐� 鞝滌稖頃橂姅 韴瀽 鞛愲靷澊氅�, 攴� 欷� Highbridge Tactical Credit Master Fund, L.P.臧� 頃措嫻 韥措灅鞀れ潣 5%毳� 齑堦臣 氤挫湢頃橁碃 鞛堨潓鞚� 瓿店皽頃╇媹雼�.
Highbridge Capital Management, LLC d茅clare la propri茅t茅 b茅n茅ficiaire de bons de souscription convertibles en 8听000听000 actions ordinaires de Reviva Pharmaceuticals Holdings, Inc., repr茅sentant 9,9听% de la cat茅gorie apr猫s prise en compte d鈥檜ne offre d茅crite dans le suppl茅ment au prospectus de l鈥櫭﹎etteur du 26 juin 2025 et soumis 脿 une clause de blocage de 9,9听% contractuelle. Le d茅p么t pr茅cise que le chiffre de 8听000听000 refl猫te l鈥檈xercice complet des warrants d茅clar茅s, mais indique que Highbridge ne peut pas exercer des warrants dans la mesure o霉 cela ferait d茅passer la limite de d茅tention de 9,9听%, de sorte que le nombre effectivement exer莽able est limit茅 par ce blocage. La personne d茅clarante est un conseiller en investissement d茅posant au nom des fonds Highbridge et d茅clare qu鈥檜n fonds, Highbridge Tactical Credit Master Fund, L.P., d茅tient plus de 5聽% de la cat茅gorie.
Highbridge Capital Management, LLC meldet die wirtschaftliche Eigent眉merschaft an in 8.000.000 wandelbaren Optionsscheinen auf Stammaktien von Reviva Pharmaceuticals Holdings, Inc., was nach Ber眉cksichtigung eines im Prospekterg盲nzungsblatt des Emittenten vom 26. Juni 2025 beschriebenen Angebots 9,9% der Klasse entspricht und einem vertraglichen 9,9%-Blocker unterliegt. Die Einreichung stellt klar, dass die Zahl 8.000.000 den vollst盲ndigen Aus眉bungsbetrag der gemeldeten Warrants widerspiegelt, weist jedoch darauf hin, dass Highbridge Warrants nicht in dem Umfang aus眉ben kann, in dem dies die Eigentumsgrenze von 9,9% 眉berschreiten w眉rde, sodass die tats盲chlich aus眉bbaren Aktien durch diesen Blocker begrenzt sind. Die meldende Person ist ein Investmentberater, der im Namen von Highbridge-Fonds handelt, und gibt an, dass ein Fonds, Highbridge Tactical Credit Master Fund, L.P., mehr als 5% der Klasse h盲lt.
- Clear disclosure of the notional position: warrants exercisable into 8,000,000 shares
- Transparency that ownership is reported for funds managed by Highbridge and that one fund holds >5% (Highbridge Tactical Credit Master Fund, L.P.)
- Compliance with Schedule 13G reporting and certification that securities were acquired in the ordinary course of business
- Exercise limited by a contractual 9.9% blocker, so full conversion of the warrants is not currently possible
- Potential overstatement risk in cover-page share counts: reported numbers show full exercise but the blocker means actual beneficial ownership is lower
Insights
TL;DR: Routine 13G disclosure showing near-10% economic stake via warrants, constrained by a 9.9% exercise blocker.
The filing discloses that Highbridge holds warrants exercisable into 8,000,000 shares, and calculates ownership at 9.9% after accounting for the issuer's post-offering share count and the contractual 9.9% blocker. This is a standard beneficial-ownership disclosure by an investment adviser rather than an active control claim. Material points for investors include the size of the potential stake and the fact that exercise is limited by the blocker, which prevents immediate conversion to a larger equity position.
TL;DR: Disclosure signals sizeable economic interest but confirms limits on voting/control through the 9.9% blocker.
The statement is a compliance filing under Schedule 13G and emphasizes the securities were acquired in the ordinary course of business and not to influence control. Identification of a specific Highbridge fund holding over 5% is important for transparency. The 9.9% blocker is explicitly acknowledged, reducing the potential for immediate governance influence despite the large notional position.
Highbridge Capital Management, LLC dichiara la propriet脿 effettiva di warrant convertibili in 8.000.000 azioni ordinarie di Reviva Pharmaceuticals Holdings, Inc., pari al 9,9% della categoria dopo aver considerato un鈥檕fferta descritta nel supplemento al prospetto dell鈥檈mittente del 26 giugno 2025 e soggette a una clausola contrattuale di blocco del 9,9%. Il deposito chiarisce che la cifra di 8.000.000 riflette l鈥檈sercizio completo dei warrant dichiarati, ma precisa che Highbridge non pu貌 esercitare i warrant nella misura in cui ci貌 porterebbe a superare il limite di propriet脿 del 9,9%, quindi il numero effettivamente esercitabile 猫 limitato da tale clausola. La persona che presenta la dichiarazione 猫 un gestore di investimenti che agisce per conto dei fondi Highbridge e dichiara che un fondo, Highbridge Tactical Credit Master Fund, L.P., detiene oltre il 5% della categoria.
Highbridge Capital Management, LLC informa de la propiedad beneficiaria de warrants convertibles en 8.000.000 acciones ordinarias de Reviva Pharmaceuticals Holdings, Inc., lo que representa el 9,9% de la clase despu茅s de considerar una oferta descrita en el suplemento del prospecto del emisor del 26 de junio de 2025 y sujeto a un contratual bloqueo del 9,9%. La presentaci贸n aclara que la cifra de 8.000.000 refleja el ejercicio total de los warrants informados, pero se帽ala que Highbridge no puede ejercer warrants en la medida en que ello supere el l铆mite de propiedad del 9,9%, por lo que las acciones realmente ejercitables est谩n limitadas por dicho bloqueo. La persona que informa es un asesor de inversiones que presenta en nombre de los fondos Highbridge y divulga que un fondo, Highbridge Tactical Credit Master Fund, L.P., posee m谩s del 5% de la clase.
Highbridge Capital Management, LLC電� Reviva Pharmaceuticals Holdings, Inc. 氤错喌欤� 8,000,000欤茧 鞝勴櫂 臧�電ロ暅 鞗岆煱韸胳潣 鞁れ鞝� 靻岇湢毳� 氤搓碃頃橂┌, 鞚措姅 氚滍枆鞚胳澊 2025雲� 6鞗� 26鞚检瀽 氤挫订靹る獏靹滌棎 旮办灛霅� 瓿惦毳� 氚橃榿頃� 頉� 頃措嫻 膦呺鞚� 9.9%鞐� 頃措嫻頃橁碃 瓿勳暯靸� 9.9% 彀嫧臁绊暛鞚� 鞝侅毄鞚� 氚涭姷雼堧嫟. 鞝滌稖靹滊電� 8,000,000鞚措澕電� 靾橃箻臧� 氤搓碃霅� 鞗岆煱韸胳潣 鞝勳暋 頄夓偓 旮办鞛勳潉 氇呿檿頌� 頃橂倶, Highbridge電� 靻岇湢 牍勳湪鞚� 9.9%毳� 齑堦臣頃橁矊 霅橂姅 氩旍渼鞐愳劀電� 鞗岆煱韸鸽ゼ 頄夓偓頃� 靾� 鞐嗢溂氙�搿� 鞁れ牅搿� 頄夓偓 臧�電ロ暅 欤检嫕 靾橂姅 攴� 彀嫧臁绊暛鞐� 鞚橅暣 鞝滍暅霅滊嫟瓿� 氇呾嫓頃╇媹雼�. 氤搓碃鞚胳潃 Highbridge 韼�霌滊ゼ 雽�鞁犿晿鞐� 鞝滌稖頃橂姅 韴瀽 鞛愲靷澊氅�, 攴� 欷� Highbridge Tactical Credit Master Fund, L.P.臧� 頃措嫻 韥措灅鞀れ潣 5%毳� 齑堦臣 氤挫湢頃橁碃 鞛堨潓鞚� 瓿店皽頃╇媹雼�.
Highbridge Capital Management, LLC d茅clare la propri茅t茅 b茅n茅ficiaire de bons de souscription convertibles en 8听000听000 actions ordinaires de Reviva Pharmaceuticals Holdings, Inc., repr茅sentant 9,9听% de la cat茅gorie apr猫s prise en compte d鈥檜ne offre d茅crite dans le suppl茅ment au prospectus de l鈥櫭﹎etteur du 26 juin 2025 et soumis 脿 une clause de blocage de 9,9听% contractuelle. Le d茅p么t pr茅cise que le chiffre de 8听000听000 refl猫te l鈥檈xercice complet des warrants d茅clar茅s, mais indique que Highbridge ne peut pas exercer des warrants dans la mesure o霉 cela ferait d茅passer la limite de d茅tention de 9,9听%, de sorte que le nombre effectivement exer莽able est limit茅 par ce blocage. La personne d茅clarante est un conseiller en investissement d茅posant au nom des fonds Highbridge et d茅clare qu鈥檜n fonds, Highbridge Tactical Credit Master Fund, L.P., d茅tient plus de 5聽% de la cat茅gorie.
Highbridge Capital Management, LLC meldet die wirtschaftliche Eigent眉merschaft an in 8.000.000 wandelbaren Optionsscheinen auf Stammaktien von Reviva Pharmaceuticals Holdings, Inc., was nach Ber眉cksichtigung eines im Prospekterg盲nzungsblatt des Emittenten vom 26. Juni 2025 beschriebenen Angebots 9,9% der Klasse entspricht und einem vertraglichen 9,9%-Blocker unterliegt. Die Einreichung stellt klar, dass die Zahl 8.000.000 den vollst盲ndigen Aus眉bungsbetrag der gemeldeten Warrants widerspiegelt, weist jedoch darauf hin, dass Highbridge Warrants nicht in dem Umfang aus眉ben kann, in dem dies die Eigentumsgrenze von 9,9% 眉berschreiten w眉rde, sodass die tats盲chlich aus眉bbaren Aktien durch diesen Blocker begrenzt sind. Die meldende Person ist ein Investmentberater, der im Namen von Highbridge-Fonds handelt, und gibt an, dass ein Fonds, Highbridge Tactical Credit Master Fund, L.P., mehr als 5% der Klasse h盲lt.
FAQ
What stake in RVPH does Highbridge report?
Are the reported RVPH shares currently exercisable?
Which Highbridge fund holds more than 5% of RVPH?
Does this Schedule 13G indicate Highbridge seeks control of RVPH?
What issuer information is included in the filing?
